SCHEMBL4143236

SCHEMBL4143236

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C\c3ccc(-c4ccc(O)c(F)c4)cc3)S2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.37
PRMT1 Q99873 1/20 0.37
ALOX5 P09917 6/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP17A1 P05093 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
CISD1 Q9NZ45 1/20 0.35
PTPN22 Q9Y2R2 1/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
PDE4B Q07343 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143240 1.00 PRMT5 (0.37) PRMT5PRMT1ALOX5KDM4ELMNA
SCHEMBL4122531 0.87 ALOX5 (0.46) ALOX5LMNAPTPN22MEN1MAPT
SCHEMBL4122528 0.87 ALOX5 (0.46) ALOX5LMNAPTPN22MEN1MAPT
SCHEMBL4132445 0.86 FFAR1 (0.47) ALOX5LMNAPDE4BGAADUSP3
SCHEMBL4132443 0.86 FFAR1 (0.47) ALOX5LMNAPDE4BGAADUSP3
SCHEMBL4127839 0.85 PDE4B (0.42) ALOX5CISD1PTPN22POLBPDE4B
SCHEMBL4127838 0.85 PDE4B (0.42) ALOX5CISD1PTPN22POLBPDE4B
SCHEMBL4635275 0.84 ALOX5 (0.42) ALOX5PTPN22KMT2ADUSP3DUSP22
SCHEMBL4634749 0.84 ALOX5 (0.52) ALOX5PTPN22MEN1KMT2A
SCHEMBL4634747 0.84 ALOX5 (0.52) ALOX5PTPN22MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PRMT5 2528/4885PRMT1 2330/4885ALOX5 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.